Cribstone Capital Management LLC boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 8.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 625 shares of the medical research company’s stock after buying an additional 50 shares during the period. Cribstone Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $109,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of TMO. Quadrature Capital Ltd bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $4,745,000. Perigon Wealth Management LLC increased its position in Thermo Fisher Scientific by 21.4% in the fourth quarter. Perigon Wealth Management LLC now owns 30,230 shares of the medical research company’s stock valued at $4,842,000 after buying an additional 5,325 shares during the period. HighPoint Advisor Group LLC increased its position in Thermo Fisher Scientific by 4.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,028 shares of the medical research company’s stock valued at $324,000 after buying an additional 79 shares during the period. Whalerock Point Partners LLC increased its position in Thermo Fisher Scientific by 21.6% in the fourth quarter. Whalerock Point Partners LLC now owns 2,815 shares of the medical research company’s stock valued at $398,000 after buying an additional 500 shares during the period. Finally, Kentucky Retirement Systems bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $4,045,000. Institutional investors and hedge funds own 87.15% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at 173.23 on Friday. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The stock has a market cap of $67.58 billion, a PE ratio of 30.18 and a beta of 1.06. The stock has a 50 day moving average of $176.78 and a 200 day moving average of $165.46.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.03 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.
Several research firms recently weighed in on TMO. Bank of America Corporation upped their price target on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Jefferies Group LLC upped their price target on shares of Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a “hold” rating in a research report on Friday, April 28th. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Citigroup Inc. restated a “buy” rating and set a $201.00 price target (up previously from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $188.56.
In related news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the transaction, the chief executive officer now owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel P. Shine sold 4,688 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total transaction of $805,773.44. Following the transaction, the insider now directly owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last three months, insiders sold 27,188 shares of company stock valued at $4,702,223. Company insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.